Legend:
CC = Vancouver Convention Centre
F = Fairmont Waterfront Vancouver
* = applied session ! = JSM meeting theme
|
|
|
|
484 !
|
Wed, 8/1/2018,
8:30 AM -
10:20 AM
|
CC-West 121
|
|
Clinical Trial Design- 5 — Contributed Papers
|
|
Biopharmaceutical Section
|
|
Chair(s): Jane Qian, Abbvie
|
|
8:35 AM
|
Moving Beyond Longrank/Hazard Ratio Test/Estimation Approach in Cancer Clinical Trials
Hajime Uno, Dana Farber Cancer Institute; Miki Horiguchi, Kitasato University
|
|
8:50 AM
|
Sample Size Allocation in Multi-Regional Equivalence Studies
Jason Liao, Merck & Co. Inc.; Ziyi Yu, Jazz Pharmaceuticals Inc; Yulan Li, Myovant Sciences
|
|
9:05 AM
|
BLINDED SAMPLE SIZE RE-ESTIMATION
Chien-Hua Wu, Chung-Yuan Christian University; Shu-Mei Wan, Lunghwa University of Science and Technology
|
|
9:20 AM
|
A Model-Based Approach for Simulating Adaptive Clinical Studies with Surrogate Endpoints Used for Interim Decision-Making
Xiaotian Chen, AbbVie; Alan Hartford, AbbVie Inc; Mei Li, AbbVie; Jun Zhao, AbbVie
|
|
9:35 AM
|
A Curtailed Two-Stage Selection and Testing Procedure for Comparative Clinical Trials
Mingyue Wang, Syracuse University; Pinyuen Chen, Syracuse University
|
|
9:50 AM
|
Longitudinal Parametric Dose-Response Surface Model Assisted Early Phase Study Design
Yongming Qu, Eli Lilly and Company
|
|
10:05 AM
|
Assessment of Treatment Effect on Overall Survival in the Presence of Treatment Switching: a Bridging Approach Across Various Modeling Methods
Yiyun Tang, Pfizer, Inc.; Selaru Paulina, Pfizer Inc.; Xin Huang, Pfizer Inc.
|
